Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer

Journal of Bone and Mineral Metabolism

Volumn 30, Issue 4, 2012, Pages 461-467

  Sergi, Giuseppe ^a,b   Pintore, Giulia ^a   Falci, Cristina ^c   Veronese, Nicola ^a   Berton, Linda ^a   Perissinotto, Egle ^a   Basso, Umberto ^c   Brunello, Antonella ^c   Monfardini, Silvio ^c   Manzato, Enzo ^a   Coin, Alessandra ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Division of Geriatrics   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Anastrozole; Early breast cancer; Elderly; Osteoporosis; Vertebral fractures

Indexed keywords

ANASTROZOLE; CALCIUM CARBONATE; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; BODY HEIGHT; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; EARLY BREAST CANCER; EARLY CANCER; FEMALE; FEMUR NECK; FOLLOW UP; FRAGILITY FRACTURE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; SIDE EFFECT; THORACIC SPINE; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; BREAST NEOPLASMS; CALCIUM CARBONATE; COHORT STUDIES; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; NITRILES; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; SEVERITY OF ILLNESS INDEX; TRIAZOLES; VITAMIN D;

EID: 84863867766     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-011-0341-1     Document Type: Article

References (28)

1. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139 (Pubitemid 34694019)
2. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group (2005) ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
3. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J, ABCSG and the GABG (2005) On behalf of the ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462 (Pubitemid 41111693)
4. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group (2006) Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial. J Bone Miner Res 21:1215-1223 (Pubitemid 44128334)
5. Geisler J, Lønnig PE (2010) Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol 118:294-299
6. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ 3rd, Riggs BL (2002) Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Mineral Res 17:172-178 (Pubitemid 33151009)
7. McCaig FM, Renshaw L, Williams L (2010) A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 119:643-651
8. Ortmann O, Cufer T, Dixon JM, Maass N, Marchetti P, Pagani O, Pronzato P, Semiglazov V, Spano JP, Vrdoljak E, Wildiers H (2009) Adjuvant endocrine therapy for perimenopausal women with early breast cancer. Breast 18:2-7
9. Tirona MT, Sehgal R, Ballester O (2010) Prevention of breast cancer (part 1): epidemiology, risk factors, and risk assessment tools. Cancer Invest 28:743-750
10. Thomas GA, Leonard RC (2009) How age affects the biology of breast cancer. Clin Oncol 21:81-85
11. Anderson WF, Chu KC, Chang S, Sherman ME (2004) Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 13:1128-1135 (Pubitemid 38917901)
12. Boonen S, Dejaeger E, Vanderschueren D, Venken K, Bogaerts A, Verschueren S, Milisen K (2008) Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 22:765-785
13. Hoyland JA, Baris C, Wood L, Baird P, Selby PL, Freemont AJ, Braidman IP (1999) Effect of ovarian steroid deficiency on oestrogen receptor alpha expression in bone. J Pathol 188:294-303 (Pubitemid 29317774)
14. WHO (World Health Organization Technical Report) (1994) Assessment of fracture risk and its applications to screening for menopausal osteoporosis: report of a WHO Study Group. Geneva, Switzerland
15. Guglielmi G, Stoppino LP, Placentino MG, D'Errico F, Palmieri F (2009) Reproducibility of a semi-automatic method for 6-point vertebral morphometry in a multi-centre trial. Eur J Radiol 69:173-178
16. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
17. Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E (2007) Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. Clin Ther 29:1937-1949
18. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91 (Pubitemid 30099515)
19. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352 (Pubitemid 29483192)
20. Von Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R (2010) Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE Trial. J Clin Oncol 28:967-975
21. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188-2194
22. Markopoulos C, Tzoracoleftherakis E, Polychronis A, Venizelos B, Dafni U, Xepapadakis G, Papadiamantis J, Zobolas V, Misitzis J, Kalogerakos K, Sarantopoulou A, Siasos N, Koukouras D, Antonopoulou Z, Lazarou S, Gogas H (2010) Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24
23. Takakuwa M, Iwamoto J, Konishi M, Zhou Q, Itabashi K (2011) Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study. J Bone Miner Metab 29:88-95
24. Pazianas M, Abrahamsen B (2011) Safety of bisphosphonates. Bone (NY) 49:103-110
25. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL (2009) Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 116:433-439
26. Cosman F (2003) Selective estrogen-receptor modulators. Clin Geriatr Med 19:371-379
27. Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L (2011) The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord 12:209
28. Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res Treat 129:495-503